Publications
Peer-Reviewed Journal Articles and Abstracts
Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.

External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa).

Conference Coverage
Conference Highlights from Recent Conference Coverage
Presented by Daniel J. George, MD
Dr. Daniel George and colleagues presented a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. 
Presented by Neal Shore, MD, FACS
(UroToday.com) Neal Shore, MD, FACS, presented the HERO Phase III trial assessing the role of relugolix, an oral GnRH receptor antagonist, compared to leuprolide acetate for advanced prostate cancer. Prostate cancer is the most common cancer diagnosis and the second most common cause of cancer death in US men, as shown in Figure 1. It is also known that cardiovascular mortality is the leading cause of death in patients with prostate cancer.
Presented by Elahe A. Mostaghel, MD, PhD
(UroToday.com) As part of the 2020 ASCO Virtual Annual Meeting Prostate Cancer Oral Abstract Session, Dr. Elahe Mostaghel from Fred Hutchinson Cancer Research Center in Seattle, Washington, provided a discussant presentation assessing the role of androgen deprivation therapy (ADT) for advanced prostate cancer.
Presented by Neal Shore, MD, FACS
(UroToday.com) Androgen deprivation is the backbone of treatment for men with metastatic prostate cancer. The current standard of care is leuprolide or degarelix, both given as subcutaneous injections. While degarelix is only available as a one-month formulation, leuprolide is available in 1, 3, or 6-month depo injections, which offers significant convenience for patients.
Presented by Neal D. Shore, MD, FACS
LHRH agonists are the mainstay for medical castration in advanced prostate cancer, however, they cause an initial testosterone surge with a delayed onset of castration and require depot injection. Although prostate cancer is the most common cancer diagnosis and the second most common cause of cancer death in US men, cardiovascular mortality is the leading cause of death in patients with prostate cancer.  Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels.